How to Find the Right CDMO for Your Manufacturing Program

Before searching for a CDMO, define what the program actually needs.

That may sound obvious, but many sourcing efforts begin with company research before the selection criteria are clear.

A team may know it needs a biologics CDMO, a fill finish partner, or a small molecule manufacturer, but that still leaves a large universe of possible companies.

The search becomes more useful when the sponsor defines the requirements that could materially affect manufacturing fit.

These can include modality, development stage, required capabilities, regulatory expectations, production scale, project timing, geography, budget, and the level of technical or operational support the program requires.

The more clearly those requirements are defined, the easier it becomes to separate plausible manufacturing partners from companies that are only loosely relevant.

A broad search such as “biologics CDMO” can be a useful starting point.

It is rarely enough to make a shortlist.

Two CDMOs may both market biologics manufacturing services while supporting very different types of projects, scales, facilities, technologies, and development stages.

The same problem appears across nearly every manufacturing category.

A company may offer small molecule manufacturing but focus on a different scale or type of chemistry. A fill finish provider may support vials but not the delivery format or production requirements needed by the sponsor. A cell therapy manufacturer may work in the correct modality but not at the required stage or facility configuration.

That is why CDMO sourcing should move from:

Who offers this general service?

to:

Who appears equipped to support this specific manufacturing program?

There is no single source that contains every useful CDMO option.

Sponsors often combine several discovery methods.

Industry relationships and referrals can surface manufacturers that colleagues have worked with previously. Consultants may provide recommendations based on their experience. Conferences can introduce teams to manufacturing providers they had not encountered before. CDMO directories and databases can help identify companies by service or modality. Search engines can uncover specialized providers, regional manufacturers, and companies outside an existing network.

All of these methods can be useful.

The problem arises when discovery becomes the end of the process rather than the beginning.

A referral is still a candidate.

A directory listing is still a candidate.

A company found through Google is still a candidate.

Each one needs to be evaluated against the program.

A CDMO directory can save time when the goal is simply to identify companies operating in a particular manufacturing category.

It can also help sponsors discover manufacturers outside their existing network.

But directory information is often company-level and broad.

A listing may show that a CDMO works in biologics, small molecules, viral vectors, fill finish, or another area. That does not automatically tell the sponsor which facility would support the project, what equipment is available, what scale the site operates at, or whether the manufacturer is a strong fit for the current stage of development.

Directories are therefore most useful near the top of the sourcing funnel.

They answer:

Who might be worth looking at?

They do not necessarily answer:

Who appears to fit this program best?

Large global CDMOs are often the first names sponsors recognize.

They can be strong partners for many programs, but size alone should not determine the shortlist.

Smaller and mid-sized manufacturers may offer specialized capabilities, different project economics, more flexible operating models, or greater interest in smaller biotech programs.

The right partner depends on the project.

A startup preparing for first-in-human development may value flexibility and technical support differently from a large pharmaceutical company planning commercial supply.

A good CDMO search therefore includes manufacturers that fit the requirements, not just manufacturers with the highest brand recognition.

A company name can hide a great deal of complexity.

Many CDMOs operate multiple manufacturing facilities.

Those sites may support different modalities, production scales, equipment, technologies, regulatory markets, or service areas.

If the program will ultimately be placed at one specific facility, then facility-level fit matters.

Sponsors should therefore try to move from:

Which CDMO should we consider?

to:

Which CDMO and which facility should we investigate?

Where available, Pharma Connect Navigator includes facility-level information to make that distinction easier during the sourcing process.

Once a set of potential CDMOs has been identified, the next step is to eliminate obvious mismatches.

Technical relevance may depend on the modality, required manufacturing capabilities, production scale, regulatory requirements, facility characteristics, equipment, or other program-specific needs.

This step prevents teams from spending time researching companies that were unlikely to support the project in the first place.

It also reduces unnecessary outreach.

A more focused shortlist means the sponsor can spend more time investigating companies that have a plausible reason to be there.

Technical capability does not automatically make a manufacturer the right partner.

Sponsors may also need to consider development stage, project kickoff, geography, budget, batch size, support services, and other operating preferences.

These factors may not always determine whether a company is technically capable of supporting the project, but they can significantly affect how attractive that company is relative to other options.

This distinction matters.

A technically relevant CDMO can still be a poor practical fit.

A useful CDMO shortlist should be explainable.

For each company, the team should be able to say why that manufacturer is being considered.

A simple sourcing framework might look like this:

The shortlist does not need to be perfect at this stage.

It needs to be defensible.

Once a company makes the shortlist, conduct enough research to determine whether it still appears worth contacting.

That may include reviewing the relevant manufacturing facility, technical capabilities, equipment, regulatory information, and other available information.

Once potential manufacturers have been identified, the guide on how to choose a CDMO covers the selection criteria used to narrow the shortlist.

It is an early filter.

The objective is to avoid beginning detailed conversations with every company that appeared in the initial search.

There is rarely one objectively “best CDMO.”

The appropriate manufacturing partner depends on the program.

A manufacturer that looks excellent for one sponsor may be poorly suited to another.

That is why PCN uses project-specific matching rather than trying to produce one universal ranking of CDMO companies.

The same manufacturer can receive a different Match % for different programs because the requirements and priorities are different.

One of the biggest weaknesses of referral-driven sourcing is that a sponsor can only be referred to companies its network already knows.

That may be perfectly adequate for some programs.

In other cases, it can limit the search.

A structured CDMO search can help sponsors look beyond familiar names and investigate specialized or less obvious manufacturing partners that appear relevant to the project.

The purpose is not to eliminate referrals.

It is to avoid making referrals the only source of candidates.

Pharma Connect Navigator is a project-based CDMO search, sourcing, matching, preliminary diligence, and sponsor-CDMO connection platform.

Sponsors start by defining the requirements of the manufacturing program.

PCN then helps identify CDMO companies and facilities that appear relevant to those requirements.

Users can compare project fit, investigate available company and facility information, review manufacturing capabilities, equipment, and regulatory context, and decide which manufacturers are worth advancing.

The process can then move into a structured introduction request, giving the CDMO enough context to determine whether it is interested in the opportunity.

The goal is not simply to produce more CDMO names.

It is to help sponsors move from a broad manufacturing market to a better-qualified shortlist.

A structured search usually follows a straightforward sequence:

1. Define the program→
2. Discover potential CDMOs→
3. Match requirements→
4. Compare fit→
5. Conduct preliminary diligence→
6. Contact manufacturers worth advancing

Each stage removes uncertainty.

By the time outreach begins, the sponsor should have a clearer understanding of why each manufacturer is being contacted.

That creates a better starting point for both sides.